UK markets closed

BioInvent International AB (publ) (0H22.L)

LSE - LSE Delayed price. Currency in SEK
Add to watchlist
44.540.00 (0.00%)
At close: 05:13PM BST

BioInvent International AB (publ)

The Gamma Building
Ideongatan 1
Lund 223 70
Sweden
46 4 62 86 85 50
https://www.bioinvent.com

Sector(s)
Industry
Full-time employees111

Key executives

NameTitlePayExercisedYear born
Dr. Martin Welschof Ph.D.President & CEO5.06MN/A1961
Mr. Stefan Ericsson M.B.A.Chief Financial OfficerN/AN/A1963
Ms. Marie Moores M.Sc., R.G.N.Chief Operating OfficerN/AN/AN/A
Mr. Kristoffer Rudenholm HanssonSenior Vice President of Technical OperationsN/AN/A1974
Mr. Björn FrendéusChief Scientific Officer2.35MN/A1973
Ms. Cecilia HofvanderSenior Director of Investor RelationsN/AN/A1967
Dr. Andres McAllisterChief Medical OfficerN/AN/A1956
Ms. Ingrid TeigeHead of Preclinical ResearchN/AN/AN/A
Ms. Sylvie RyckebuschChief Business OfficerN/AN/AN/A
Dr. Ingunn Munch LindvigSenior Vice President of Regulatory AffairsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.

Corporate governance

BioInvent International AB (publ)’s ISS governance QualityScore as of 1 April 2024 is 5. The pillar scores are Audit: 9; Board: 3; Shareholder rights: 1; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.